Annual report pursuant to Section 13 and 15(d)

Commitments and Contingencies (Details Narrative)

v3.20.1
Commitments and Contingencies (Details Narrative)
12 Months Ended
Nov. 03, 2018
USD ($)
Sep. 12, 2018
USD ($)
Aug. 20, 2018
USD ($)
Jun. 14, 2018
USD ($)
Apr. 05, 2018
USD ($)
Apr. 05, 2018
EUR (€)
Apr. 02, 2018
Mar. 22, 2018
USD ($)
Jul. 09, 2017
USD ($)
Jun. 14, 2017
USD ($)
Sep. 14, 2015
USD ($)
Dec. 24, 2013
USD ($)
Dec. 31, 2019
USD ($)
Dec. 31, 2018
USD ($)
Research and development costs                         $ 820,906 $ 40,703
Unamortized balance of the retainer payment classified as a non-current asset                         2,293
Accreted charges                           25,000
Reversal of accreted charges                           25,000
NDA Consulting Corp [Member]                            
Agreement term                       1 year    
Consulting and advisory fee                       $ 4,000 16,000 16,000
Clinical Trial Research Agreement [Member]                            
Research and development costs                         45,093  
Clinical Trial Research Agreement [Member] | Moffitt Cancer Center and Research Institute Hospital Inc [Member]                            
Research and development costs                         45,093 0
Collaboration Agreement [Member]                            
Research and development costs                         87,471  
Collaboration Agreement [Member] | BioPharmaWorks LLC [Member]                            
Research and development costs                         100,000 10,000
Consulting and advisory fee                     $ 10,000      
Collaboration Agreement [Member] | Grupo Espanol de Investigacion en Sarcomas [Member]                            
Research and development costs                         87,471  
Clinical Trial Agreement [Member]                            
Aggregate commitments expected                         $ 5,000,000  
Aggregate commitments expected, description                         The Company's aggregate commitments pursuant to these clinical trial agreements, less amounts previously incurred to date under these agreements, totaled approximately $5,000,000 as of December 31, 2019, which are expected to be incurred over the next five years through 2024.  
Work Order Agreement [Member]                            
Research and development costs                         $ 63,492  
Work Order Agreement [Member] | Theradex Systems, Inc [Member]                            
Research and development costs   $ 954,000                     51,586 11,906
Payment expected dividend for pass-through costs, description   The clinical trial is expected to be completed over a period of two years, with final analysis and reporting expected within three years. Costs under this work order agreement are estimated to be approximately $954,000, with such payments expected to be divided approximately 94% to Theradex for services and approximately 6% for payments for pass-through costs.                        
Material Transfer Agreement [Member] | INSERM [Member] | Development Milestones [Member] | Maximum [Member]                            
Milestone payments               $ 1,750,000            
Material Transfer Agreement [Member] | INSERM [Member] | Commercial Milestones [Member] | Maximum [Member]                            
Milestone payments               $ 6,500,000            
Consulting Agreement with Liberi Life Consultancy BV [Member]                            
Agreement term             2 years              
Payment of a fixed, one-time retainer one time retainer         $ 18,348                  
Net payments of sales of products or licensing activities, percentage         2.50% 2.50%                
Consulting Agreement with Liberi Life Consultancy BV [Member] | EURO [Member]                            
Payment of a fixed, one-time retainer one time retainer | €           € 15,000                
Consulting Agreement [Member]                            
Amortizing the retainer payment                         9,174 6,881
Unamortized balance of the retainer payment                         $ 2,294 11,468
Unamortized balance of the retainer payment classified as a current asset                           9,175
Unamortized balance of the retainer payment classified as a non-current asset                           2,293
Royalties description                         The Company will be obligated to pay Moffitt earned royalties of 4% on worldwide cumulative net sales of royalty-bearing products, subject to reduction to 2% under certain circumstances, on a quarterly basis, with a minimum royalty payment of $50,000 in the first four years after sales commence, and $100,000 in year five and each year thereafter, subject to reduction by 40% under certain circumstances relating to the status of Valid Claims, as such term is defined in the License Agreement.  
Exclusive License Agreement [Member]                            
Amount charges to operations                         $ 80,669 $ 0
Exclusive License Agreement [Member] | First Four Years [Member]                            
Minimum payments for royalties                         50,000  
Exclusive License Agreement [Member] | Five Years and Thereafter [Member]                            
Minimum payments for royalties                         $ 100,000  
Exclusive License Agreement [Member] | Moffitt Cancer Center and Research Institute Hospital Inc [Member]                            
Non-refundable license issue fee     $ 25,000                      
Clinical trial analysis expected term     2 years                      
Clinical trial final analysis expected term     3 years                      
Annual license maintenance fee     $ 25,000                      
Payments on non-refundable milestone     $ 1,897,000                      
Percentage of milestone     40.00%                      
Materials Cooperative Research and Development Agreement [Member]                            
Funds provide for use in acquiring technical, statistical and administrative support for research activities                   $ 100,000        
Materials Cooperative Research and Development Agreement [Member] | First Installment [Member]                            
Paid two equal installments                 $ 50,000          
Materials Cooperative Research and Development Agreement [Member] | Second Installment [Member]                            
Paid two equal installments       $ 50,000                    
Cancellation of installment, amount $ 50,000